Patient-Oriented Evidence That Matters
Lipid Lowering Is Beneficial for Secondary Prevention but Not Primary Prevention in Patients 75 Years and Older
Am Fam Physician. 2021 Jun 1;103(11):695-696.
Does lipid lowering reduce major vascular events in patients 75 years and older?
This meta-analysis inappropriately conflates studies of primary and secondary prevention, and the authors argue that their data support the use of lipid-lowering drugs in older adults. That may be true for secondary prevention, but it is clearly not proven for primary prevention. The STAREE trial is currently recruiting 18,000 older adults and randomizing them to receive atorvastatin (Lipitor), 40 mg, or placebo, and it will hopefully provide greater clarity about the use of lipids for primary prevention (results expected in 2023). (Level of Evidence = 1a−)
Previous studies have found attenuation of the benefit of statins in older patients, especially in those older than 75 years. This meta-analysis included 24 of 28 studies from an individual patient data meta-analysis of statin trials (excluding four studies that were limited to patients with heart failure or who were on dialysis), as well as a newly published statin trial, two ezetimibe (Zetia) trials, and two proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor trials. The authors treat the individual patient data meta-analysis as a single large study: it provided 11,108 of the 21,492 patients 75 years and older in this meta-analysis. The other studies ranged in size from 642 to 3,411 patients. It is important to note that many of the studies in the individual patient data meta-analysis and four of the five other studies were of secondary prevention rather than primary prevention. For the statin trials, the relative risk of major vascular events (i.e., cardiovascular death, myocardial infarction, acute coronary syndrome, coronary revascularization, or stroke) was 0.82 (95% CI, 0.73 to 0.91). For the four nonstatin trials, the relative risk was 0.67, but with a broader confidence interval (95% CI, 0.47 to 0.95). The authors then provided a combined estimate for statin and nonstatin trials,
POEMs (patient-oriented evidence that matters) are provided by Essential Evidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.
For definitions of levels of evidence used in POEMs, see http://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.
To subscribe to a free podcast of these and other POEMs that appear in AFP, search in iTunes for “POEM of the Week” or go to http://goo.gl/3niWXb.
This series is coordinated by Sumi Sexton, MD, editor-in-chief.
A collection of POEMs published in AFP is available at https://www.aafp.org/afp/poems.
Want to use this article elsewhere? Get Permissions